Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
38
PHAT Quote, Financials, Valuation and Earnings
Last price:
$17.54
Seasonality move
:
-12.11%
Day range:
$17.36 - $17.74
52-week range:
$2.21 - $18.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.62x
P/B ratio:
--
Volume:
362.6K
Avg. volume:
922.3K
1-year change:
116.79%
Market cap:
$1.2B
Revenue:
$55.3M
EPS (TTM):
-$3.81
Analysts' Opinion
-
Consensus RatingPhathom Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.90, Phathom Pharmaceuticals, Inc. has an estimated upside of 30.41% from its current price of $17.56.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $17.56.
Fair Value
-
According to the consensus of 10 analysts, Phathom Pharmaceuticals, Inc. has 30.41% upside to fair value with a price target of $22.90 per share.
PHAT vs. S&P 500
-
Over the past 5 trading days, Phathom Pharmaceuticals, Inc. has overperformed the S&P 500 by 6.38% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Phathom Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Phathom Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Phathom Pharmaceuticals, Inc. reported revenues of $49.5M.
Earnings Growth
-
Phathom Pharmaceuticals, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Phathom Pharmaceuticals, Inc. reported earnings per share of -$0.41.
Enterprise value:
1.7B
EV / Invested capital:
--
Price / LTM sales:
8.62x
EV / EBIT:
--
EV / Revenue:
11.53x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-7.53x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$128.4M
Return On Assets:
-88.55%
Net Income Margin (TTM):
-186.53%
Return On Equity:
--
Return On Invested Capital:
-115.48%
Operating Margin:
-30.85%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $26.3M | $147.2M | $16.4M | $49.5M | |
| Gross Profit | -$558K | $21.8M | $128.4M | $14M | $43.3M | |
| Operating Income | -$144.1M | -$287.9M | -$213.5M | -$70.8M | -$15.3M | |
| EBITDA | -$143.5M | -$287.1M | -$212.8M | -$70.6M | -$15.1M | |
| Diluted EPS | -$3.83 | -$5.69 | -$3.81 | -$1.32 | -$0.41 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $225.3M | $197.8M | $226.7M | $373.8M | $207.8M | |
| Total Assets | $228.4M | $201.9M | $237M | $387M | $240.3M | |
| Current Liabilities | $27.8M | $22.9M | $24M | $65.3M | $93.1M | |
| Total Liabilities | $124.9M | $228.4M | $254.8M | $574.2M | $662.8M | |
| Total Equity | $103.5M | -$26.4M | -$17.8M | -$187.1M | -$422.5M | |
| Total Debt | $89.6M | $206.4M | $225.7M | $518.3M | $582.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$134.5M | -$247.1M | -$225.2M | -$63.6M | -$14.1M | |
| Cash From Investing | -$1.6M | -$605K | -$147K | -$44K | -$27K | |
| Cash From Financing | $155.6M | $368.7M | $25.9M | $122.1M | -$271K | |
| Free Cash Flow | -$136.1M | -$247.7M | -$225.4M | -$63.6M | -$14.1M | |
PHAT
Sector
Market Cap
$1.2B
$28.2M
Price % of 52-Week High
95.9%
51.2%
Dividend Yield
0%
0%
Shareholder Yield
-2.04%
-1.54%
1-Year Price Total Return
116.79%
-18.1%
Beta (5-Year)
0.432
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$16.84
200-day SMA
Buy
Level
$9.72
Bollinger Bands (100)
Buy
Level
11.15 - 14.97
Chaikin Money Flow
Buy
Level
3.1M
20-day SMA
Buy
Level
$15.57
Relative Strength Index (RSI14)
Buy
Level
70.17
ADX Line
Buy
Level
33.47
Williams %R
Sell
Level
-17.8998
50-day SMA
Buy
Level
$14.63
MACD (12, 26)
Buy
Level
4.75
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
6.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.5472)
Sell
CA Score
(Annual)
Level (-7.7552)
Sell
Beneish M-Score
(Annual)
Level (67.3512)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (9.8534)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
Stock Forecast FAQ
In the current month, PHAT has received 8 Buy ratings 2 Hold ratings, and 0 Sell ratings. The PHAT average analyst price target in the past 3 months is $22.90.
-
Where Will Phathom Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Phathom Pharmaceuticals, Inc. share price will rise to $22.90 per share over the next 12 months.
-
What Do Analysts Say About Phathom Pharmaceuticals, Inc.?
Analysts are divided on their view about Phathom Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Phathom Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Phathom Pharmaceuticals, Inc.'s Price Target?
The price target for Phathom Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $22.90 according to 10 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is PHAT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Phathom Pharmaceuticals, Inc. is a Buy. 8 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PHAT?
You can purchase shares of Phathom Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Phathom Pharmaceuticals, Inc. shares.
-
What Is The Phathom Pharmaceuticals, Inc. Share Price Today?
Phathom Pharmaceuticals, Inc. was last trading at $17.54 per share. This represents the most recent stock quote for Phathom Pharmaceuticals, Inc.. Yesterday, Phathom Pharmaceuticals, Inc. closed at $17.56 per share.
-
How To Buy Phathom Pharmaceuticals, Inc. Stock Online?
In order to purchase Phathom Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PHAT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PHAT
Sector
P/E ratio
--
23.92x
PEG ratio
--
-0.01x
P/B ratio
--
1.83x
Price / LTM sales
8.62x
1.61x
Growth Metrics
PHAT
Sector
Revenue growth
202.74%
4.6%
Earnings growth
69.16%
10.88%
Revenue (5-year growth)
--
6.46%
Earnings forecast
-$0.30
-$0.21
Profitability
PHAT
Sector
Profitability FY 2024
$47.3M
$3.5M
Return on invested capital
-115.48%
-31.84%
Return on assets
-88.55%
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Jan
29
Balance Sheet
PHAT
Sector
Total cash
$135.2M
$26.3M
Short term investments
--
$25.7M
Total assets
$378.5M
$76.9M
Long term debt
$582.5M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
